Compare Allstate Corp (ALL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs IDEXX Laboratories, Inc. — how do they compare? Allstate Corp trades at $251.71 (market cap $64.77B), while IDEXX Laboratories, Inc. trades at $563.59 (market cap $44.46B). The key difference: Allstate Corp is the larger of the two by market cap, and Allstate Corp pays a 1.72% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ALL | IDXX | |
|---|---|---|
Market Cap | $64.77B | $44.46B |
Sector | Financials | Health |
52-Week High | $251.61 | $766.68 |
52-Week Low | $190.00 | $514.61 |
Enterprise Value | $73.56B | $45.36B |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
IDXX trades at $563.57, up 0.89% today, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.47 surpassing estimates. Revenue grew to $4.3B in 2025, with a robust net income margin of 24.63%. Analyst consensus is bullish with a $645 price target. Recent news highlights innovation in veterinary diagnostics and AI integration.
The outlook remains positive driven by earnings growth and market leadership, though high valuation multiples pose a risk. Key catalysts include upcoming Q2 2026 results and continued demand in pet healthcare. Risks involve competitive pressures and macroeconomic sensitivity. The stock offers growth potential but requires monitoring of valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
